AzTrials
AzTrials

HIV (Human Immunodeficiency Virus)Phase 2BOOSTNCT07221123

Boosting Olfactory and Sensory Training Study (BOOST)

A Phase 2 study testing Conventional Smell Training Group and Scented Marker Group in people with HIV (Human Immunodeficiency Virus), run by University of Alabama at Birmingham at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this study is to examine two types of olfactory interventions (conventional olfactory training vs scented marker training) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Read more about this study

Who is it for?
Ages 40 years and older
Conditions the study is for
HIV (Human Immunodeficiency Virus)
What is being tested?
Conventional Smell Training Group and Scented Marker Group
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteUnited States
Study dates
2 May 2026to 31 Dec 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participants (men \& women) must be 40+ years
  • have cognitive complaints.
  • must be proficient in English

Who cannot join

  • a sinus infection (within the past 3 months), thrush, candidiasis, pregnant, current cold or flu, hay fever, asthma, nasal allergies, opportunistic infections (including COVID-19) within the past 3 months, or current nasal obstruction condition.
  • Participation requires ~8 weeks and in-person visits, participants living beyond 60 miles away from the center will be excluded.
  • Participants living in unstable housing (e.g., shelter) or with significant neuro-comorbidities (e.g., schizophrenia) will be excluded.
  • Other conditions (e.g., legally blind/deaf, currently undergoing radiation or chemotherapy, or a history of significant brain trauma) that could impact olfactory and cognitive testing also necessitate exclusion.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

David E Vance, PhD contact

1205-934-7589

devance@uab.edu

United States1 site, 1 recruiting
  • University of Alabama at Birmingham

    Birmingham, Alabama, 35205

    David Vance, PhD, 2059151707, devance@uab.edu

    Recruiting

Other trials in United States

About this study

Official title: A Feasibility and Acceptability Study Testing Two Types of Smell Exposure Interventions in Middle-Aged Older Adults With HIV

The goal of this study is to examine two types of olfactory interventions (conventional olfactory training vs scented marker training) in adults with HIV.

The two research questions are:

Read more
  1. Determine if participants find the intervention acceptable and assess feasibility of the study.
  2. Determine if the intervention improves olfactory function and cognitive function.

Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test.

  1. Conventional Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks.
  2. Scented Marker Training at Home -- Several marker scents in which they will smell twice a day for 8 weeks.
Read the detailed description

Overall A pre-post two-group experimental design will be used. Participants will be recruited from the UAB 1917 HIV/AIDS Clinic which has a patient population of +3,900 and is the largest HIV medical provider within 100 miles. Participants will be recruited via two ways: 1) flyers posted in the UAB 1917 HIV/AIDS Clinic and 2) via 1917/CINIC participant list of participants who indicated and consented they are would like to be called for recruitment to studies (a technique used before and approved in other UAB IRB studies). Eligible participants will be consented at the UAB where a ~2 hr baseline assessment will be administered. Stratified random assignment will ensure an equal number of participants in each group by gender and smoking status. Men tend to have more olfactory dysfunction than women; therefore, it is important to control for gender upfront in the methodology. After training, participants will complete a posttest assessment.

Recruitment and Retention Procedures

Flyers. Flyers advertising the study will be provide to the UAB 1917 Clinic which they can hang or post electronically on their monitors.

Electronic Medical Record Query Using CNICS EMR Data Eligibility queries may be conducted using the CFAR Network of Integrated Clinical Systems (CNICS) EMR data. Specifically, CNICS participants (which comprise over 90% of UAB 1917 Clinic patients) have consented to be contacted to gauge interest in future studies. The Research Informatics Services Center (RISC) will provide us a list of patients meeting basic criteria (e.g., based on age, last clinic data, free from major comorbidities), and the investigators will then contact participants directly and tell them about the study and screen them over the phone as the investigators are doing in another active study protocol (RISC - IRB-300008740). When the study concludes, the investigators will also utilize RISC to yield a CNICS dataset for enrolled participants which will include basic health and HIV data (e.g., viral load).

Telephone Screen A brief telephone screening interview will be used to ensure that participants meet study inclusion/exclusion criteria. If participants meet entry criteria, they will be scheduled for a visit; appointment letters will indicate that if they develop a cold, flu, or other condition causing nasal obstruction in the interim, their appointment will be rescheduled. The appointment letter will instruct participants to refrain from eating highly aromatic foods (e.g., garlic) and abstain from liquor within 24 hrs of the appointment since these could affect olfactory tests. Thus, participants will review a signs and symptoms checklist to ensure they still meet study criteria. If they indicate they do not currently meet study criteria, they will be encouraged to participate when their situation changes. Once eligibility is confirmed, participants will sign an IRB approved consent form.

Inclusion Criteria. Participants (men \& women) must be 40+ years and have cognitive complaints. PWH 40 years of age and older are targeted due to the greater prevalence of cognitive complaints with middle and older age.89 Because the study instruments are standardized in English, participants must be proficient in English.

Exclusion Criteria. Because the following conditions can affect chemosensory (smell \& taste) abilities, participants will be excluded if they have any of the following: a sinus infection (within the past 3 months), thrush, candidiasis, pregnant, current cold or flu, hay fever, asthma, nasal allergies, opportunistic infections (including COVID-19) within the past 3 months, or current nasal obstruction condition. Participation requires ~8 weeks and in-person visits, participants living beyond 60 miles away from the center will be excluded. Participants living in unstable housing (e.g., shelter) or with significant neuro-comorbidities (e.g., schizophrenia) will be excluded. Other conditions (e.g., legally blind/deaf, currently undergoing radiation or chemotherapy, or a history of significant brain trauma) that could impact olfactory and cognitive testing also necessitate exclusion. These criteria are typical of neuroHIV and olfaction studies.

Rationale for Including Smokers. Furthering the ecological validity, the investigators will include tobacco smokers to make the study more generalizable. Our olfactory study revealed that it was difficult to recruit non-smokers given that the high prevalence of smoking in PWH (39% current and 29% former smokers).95 In our past R01 study of 260 PWH 40+, 53% were current smokers. Contrary to expectations, smoking is not associated with changes in olfaction. In fact, in our prior study, cigarettes smoked per day was not related to any cognitive or olfactory measures. In this case, smoking appears not to confound the study results. Confirming this, studies affirm that habitual smokers do not experience olfactory declines as commonly thought and actually smoking may preserve olfaction.

Recruitment and Retention Strategy. As has been effective in our prior studies, flyers will be used to recruit patients from our HIV/AIDS Clinic. Other recruitment/retention strategies include: 1. Compensation will be provided ($50 at baseline \& $50 for posttest assessment, $20 to return the completed smell training/smell exposure dairy; and $5 for each weekly questionnaire completed). 2. Telephone calls will be made and reminder letters will be sent before the scheduled visit. 3. Secondary contact information will be collected to follow up with lost participants.

Intervention Protocol At the end of the baseline visit, the investigators will randomize the participants. The research assistant will provide the participant with the smell exposure materials, diary, and instructions.

Conventional Smell Training Group - The investigators are adopting the usual smell training approach from the literature. A standard smell training kit (i.e., MOXĒ) will be used that contains the four basic odorants across the "odor prism" - i) flowery (e.g., rose), ii) resinous (e.g., eucalyptus), iii) aromatic (e.g., cloves), and iv) fruity (e.g., lemon). Participants will be instructed to sniff each of the odorant vials/bottles for 10-20 seconds twice a day (morning and evening), for the next 8 weeks. A structured daily diary will be provided for them to record observations of the experience, memories the odorants may evoke, and any side effects experienced (i.e., headache, euphoria, light headedness, phantosmia, nasal irritation).

Scented Marker Group - This group will received stored bought scented markers to be used in the same way as the Conventional Smell Training group. However, those in this group will get to choose which four scents they smell during their sessions each day. Otherwise, the protocol is the same.

Instruments (Baseline and Posttest) Because participants will be recruited through the UAB 1917 (HIV/AIDS) Clinic, the following information will be available for analysis from the electronic medical records through the CFAR Statistical Core; body mass index, most recent t-cell count, viral load, cholesterol, and serum albumin levels that correspond most closely to their study visit. Testing will be reviewed and observed every quarter to prevent drift in the protocol.

Demographic, Background, and Covariate Measures (*Baseline Only)

  • Demographic Questionnaire - Used to gather basic background characteristics (e.g., gender, ethnicity, etc). ( 2 min.) Centers for Epidemiological Studies - Depression (CES-D) scale measures how often (participants acknowledge 20 verbal depressive symptoms. Cronbach's α is very good at 0.88. (2 min.) Cognitive Complaints - Cognitive Failures Questionnaire (CFQ) - CFQ assesses common everyday cognitive complaints one may have such as in memory (e.g., "Do forget where the participant put something?"). (3 min.) Health-Related Quality of Life - Medical Outcomes Study - HIV - Short Form (SF-35) - The SF-35 includes one multi-item scale that assesses 8 health-related quality of life concepts. Cronbach's alphas for the concepts are excellent (<0.85). (10 min.)
  • HIV History/Status - Used to assess current HIV status (i.e., viral load) and general HIV infection history. (2 min.) Addiction Severity Index (ASI) - A widely used, gold standard measure of alcohol and drug use. (4 min.)
  • HIV History/Status - Used to assess current HIV status (i.e., viral load) and general HIV infection history. (2 min.)

Feasibility and Acceptability Measures A training diary will be given to participants to help them keep track of their engagement in the protocol. It will have simple check boxes for ease of use as well as space to write comments/observations. Participants will also receive a weekly call from the Principal Investigator/Research Assistant and be asked to recall how many days in the past seven have they engaged in the intervention as directed; field notes will be taken to document protocol processes that aid or interfere with the study. In addition, daily text messages Monday-Friday will be sent as reminders to encourage use of the Smell Training/Smell Exposure protocol. At the Posttest Visit after use of the Smell Exposure protocols, participants will also be asked a series of questions about what they liked and did not like about using the smelling training protocols. Many of these questions are open-ended and will be coded and used in qualitative analyses. This information will be used to determine the barriers and facilitators of the intervention. Treatment adherence will be measured by daily diaries, and posttest assessment. Study attrition will also be monitored. Many of these protocols have been used in our prior studies to document treatment fidelity and feasibility.

Olfactory Training Satisfaction Questionnaire (posttest only) - Used to assess likes/dislikes of the intervention); both quantitative questions and qualitative (i.e., open-ended responses) data are gathered as has been used in our previous cognitive intervention studies to evaluate feasibility and acceptability. (10 min.)

Side Effect Questionnaire (posttest only) - The investigators will provide a list of potential good and bad side effects of engaging in smell training/smell exposure. Participants will indicate which ones they experienced, how often, and to what degree it affected them. (5 min.) Daily Diaries (treatment monitoring) - This data collection method may provide insights into some of the experiences of those engaged in the smell training/smell exposure. It is also a source of convergent validity concerning adherence.

Attrition \& Adherence Rates (after study data collection) - The investigators will calculate the attrition rate and adherence rate of the protocol, similar to our other studies.

Olfactory (Chemosensory) Measures Smell is 10,000 times more powerful than taste, with taste being approximately 75% smell. In fact, it is the neural integration of smell and taste that produces the sensation of flavor. For these reasons, only tests of smell are used.

Smell Identification -- University of Pennsylvania Smell Identification Test (UPSIT) - The UPSIT is to smell as an eye chart is to vision and has been used extensively in the literature.115,116 Age and gender-based norms from 4,000 men and women over the lifespan have provided a percentile rank of how each participant, based on his/her sex and age, performs along a normal distribution. The UPSIT is composed of 40 test items containing 40 microencapsulated "scratch and sniff" odors. This test-retest for UPSIT is very reliable (r = 0.94). (10 min.)

Taste \& Smell Questionnaire Taste and Smell Questionnaire - Heald et al. (1998) used a smell and taste questionnaire for adults with HIV. The taste section consists of nine questions that address changes in the way food tastes. The smell section consists of five questions that address changes in the sense of smell. This measure was found to be related to the SF-36 (below)108 mental health and physical health summaries (p<.01). (50 min.)

Cognitive Measures. The investigators are using standardized pencil and paper tests of cognitive functioning such as Hopkins Verbal Learning Test, Grooved Pegboard Test, COWAT, PASAT, and Trails Making Test A \& B.

Data Analysis Data Management and Tracking. The research assistant/study coordinator will double-key enter de-identified questionnaire responses into an encrypted, password protected (front and back end) electronic database. The PI will follow-up and resolve any data queries resulting from the quality control process.

Analysis Plan. Data will be analyzed using SPSS, R, and/or SAS for simple pre-post analyses (i.e., ANCOVA). From this, effect sizes can be calculated that can be used in power analyses for future grant submissions. Also, the qualitative data will be used to modify the intervention and improve on tracking and adherence to the protocol for future studies.

Being tested
Conventional Smell Training Group, Scented Marker Group
Keywords
HIV
Medical subject headings
Acquired Immunodeficiency Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Conventional Smell Training GroupOther

    Also called olfactory training, smell training

    The investigators are adopting the usual smell training approach from the literature. A standard smell training kit (i.e., MOXĒ) will be used that contains the four basic odorants across the "odor prism" - i) flowery (e.g., rose), ii) resinous (e.g., eucalyptus), iii) aromatic (e.g., cloves), and iv) fruity (e.g., lemon). Participants will be instructed to sniff each of the odorant vials/bottles for 10-20 seconds twice a day (morning and evening), for the next 8 weeks. A structured daily diary will be provided for them to record observations of the experience, memories the odorants may evoke, and any side effects experienced (i.e., headache, euphoria, light headedness, phantosmia, nasal irritation).

  • Scented Marker GroupOther

    Also called smell training

    The investigators are adopting the store bought scented markers for the smell training approach. There are several different scents in this marker set (i.e., cherry, grape, etc.). Participants will be instructed to sniff 4 makers of their choosing for 10-20 seconds twice a day (morning and evening), for the next 8 weeks. A structured daily diary will be provided for them to record observations of the experience, memories the odorants may evoke, and any side effects experienced (i.e., headache, euphoria, light headedness, phantosmia, nasal irritation).

Study groups in NCT07221123
Study groupRoleWhat they receive
Conventional Smell Training GroupExperimentalThe investigators are adopting the usual smell training approach from the literature. A standard smell training kit (i.e., MOXĒ) will be used that contains the four basic odorants across the "odor prism" - i) flowery (e.g., rose), ii) resinous (e.g., eucalyptus), iii) aromatic (e.g., cloves), and iv) fruity (e.g., lemon). Participants will be instructed to sniff each of the odorant vials/bottles for 10-20 seconds twice a day (morning and evening), for the next 8 weeks. A structured daily diary will be provided for them to record observations of the experience, memories the odorants may evoke, and any side effects experienced (i.e., headache, euphoria, light headedness, phantosmia, nasal irritation).
Receives: Other: Conventional Smell Training Group
Scented Marker GroupExperimentalThe investigators are adopting the store bought scented markers for the smell training approach. There are several different scents in this marker set (i.e., cherry, grape, etc.). Participants will be instructed to sniff 4 makers of their choosing for 10-20 seconds twice a day (morning and evening), for the next 8 weeks. A structured daily diary will be provided for them to record observations of the experience, memories the odorants may evoke, and any side effects experienced (i.e., headache, euphoria, light headedness, phantosmia, nasal irritation).
Receives: Other: Scented Marker Group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. FEASIBILITY & ACCEPTABILITY

    A training diary will be given to participants to help them keep track of their engagement in the protocol. It will have simple check boxes for ease of use as well as space to write comments/observations. Participants will also receive a weekly call from the Principal Investigator/Research Assistant and be asked to recall how many days in the past seven have they engaged in the intervention as directed; field notes will be taken to document protocol processes that aid or interfere with the study. In addition, daily text messages Monday-Friday will be sent as reminders to encourage use of the Smell Training/Smell Exposure protocol. At the Posttest Visit after use of the Smell Exposure protocols, participants will also be asked a series of questions about what they liked and did not like about using the smelling training protocols. Many of these questions are open-ended and will be coded and used in qualitative analyses.

    Measured: From enrollment to the end of treatment at 8 weeks

Secondary outcomes (2)
  1. OLFACTION

    University of Pennsylvania Smell Identification Test (UPSIT) - The UPSIT is to smell as an eye chart is to vision and has been used extensively in the literature.115,116 Age and gender-based norms from 4,000 men and women over the lifespan have provided a percentile rank of how each participant, based on his/her sex and age, performs along a normal distribution. The UPSIT is composed of 40 test items containing 40 microencapsulated "scratch and sniff" odors. This test-retest for UPSIT is very reliable (r = 0.94). (10 min.)

    Taste and Smell Questionnaire - Heald et al. (1998) used a smell and taste questionnaire for adults with HIV. The taste section consists of nine questions that address changes in the way food tastes. The smell section consists of five questions that address changes in the sense of smell. This measure was found to be related to the SF-36 (below) mental health and physical health summaries (p<.01). (50 min.)

    Measured: From enrollment to the end of treatment at 8 weeks

  2. COGNITION _ Trail Making Test B

    The investigators are using standardized pencil and paper tests of cognitive functioning such as Trails Making Test B. This measure of executive functioning is measured in seconds required to connecting the alternating dots correctly. Lower scores (seconds) indicate better cognitive functiioning.

    Measured: From enrollment to the end of treatment at 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Oct 2025
  2. Study start2 May 2026
  3. Primary completion1 Jul 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This feasibility study employs a 2-group pre-post experimental design of 80 middle-aged (40+) and older adults with cognitive complaints including: 1) a conventional home-based Smell Training Group consisting of 8 weeks of engaging in smelling four odorants 2x/day (enroll 40, n=30 with attrition); and 2) a home-based Scented Marker Group consisting of 8 weeks of engaging in smelling several odorants 2x/day (enroll 40, n=30 with attrition)
Masking
None (open label)
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07221123
Sponsor's protocol ID
IRB - 300013575
Other IDs
UAB
Acronym
BOOST
Status last verified
Jun 2026
First submitted
23 Sep 2025
Last updated
11 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: This is a small internal pilot grant used to generate data for grant submission and for secondary data use for a PHD student at the same institution.

Publications

  • Kamath V, Del Bene VA, Collette C, Jacob A, Fazeli PL, Vance DE. A Pilot Study of Self-Rated and Psychophysical Olfactory Dysfunction in Men Living with HIV. Chemosens Percept. 2022;15(2):175-184. doi: 10.1007/s12078-022-09305-x. Epub 2022 Nov 10.

    PubMed 36406043
  • Vance D, Burrage J. Chemosensory declines in older adults with HIV: identifying interventions. J Gerontol Nurs. 2006 Jul;32(7):42-8. doi: 10.3928/00989134-20060701-06.

    PubMed 16863045
  • Vance DE, Del Bene VA, Kamath V, Frank JS, Billings R, Cho DY, Byun JY, Jacob A, Anderson JN, Visscher K, Triebel K, Martin KM, Li W, Puga F, Fazeli PL. Does Olfactory Training Improve Brain Function and Cognition? A Systematic Review. Neuropsychol Rev. 2024 Mar;34(1):155-191. doi: 10.1007/s11065-022-09573-0. Epub 2023 Feb 2.

    PubMed 36725781
  • Vance DE, Cody SL, Nicholson WC, Cheatwood J, Morrison S, Fazeli PL. The Association Between Olfactory Function and Cognition in Aging African American and Caucasian Men With HIV: A Pilot Study. J Assoc Nurses AIDS Care. 2019 Sep-Oct;30(5):e144-e155. doi: 10.1097/JNC.0000000000000086.

    PubMed 31259847
  • Vance DE, Cody SL, Nicholson C, Cheatwood J, Morrison S, Fazeli PL. Olfactory Dysfunction in Aging African American and Caucasian Men With HIV: A Pilot Study. J Assoc Nurses AIDS Care. 2022 May-Jun 01;33(3):e19-e30. doi: 10.1097/JNC.0000000000000061.

    PubMed 30676359

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Conventional Smell Training Group and Scented Marker Group in people with HIV (Human Immunodeficiency Virus), run by University of Alabama at Birmingham at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact David E Vance, PhD (1205-934-7589, devance@uab.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

FEASIBILITY & ACCEPTABILITY (time frame: From enrollment to the end of treatment at 8 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07221123, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in